These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2076932)

  • 1. Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.
    Melekos MD; Pantazakos A; Markou S; Skopa C; Athanassopoulos A; Barbalias G
    Int Urol Nephrol; 1990; 22(5):433-40. PubMed ID: 2076932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
    Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K
    J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
    Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravesical bacillus Calmette-Guerin instillation therapy in superficial bladder cancers--clinical study on prognostic factors].
    Shinka T; Hirano A; Uekado Y; Ohkawa T
    Nihon Hinyokika Gakkai Zasshi; 1990 Mar; 81(3):425-32. PubMed ID: 2359220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.
    Shinka T; Hirano A; Uekado Y; Ohkawa T
    Br J Urol; 1990 Jul; 66(1):35-9. PubMed ID: 2393797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
    Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
    J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
    Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
    J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?
    Pagano F; Bassi P; Milani C; Meneghini A; Maruzzi D; Garbeglio A
    J Urol; 1991 Jul; 146(1):32-5. PubMed ID: 2056600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule.
    Melekos MD; Chionis H; Pantazakos A; Fokaefs E; Paranychianakis G; Dauaher H
    J Urol; 1993 Apr; 149(4):744-8. PubMed ID: 8455235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer. Prospective randomized study for prophylactic effect].
    Yamamoto T; Hagiwara M; Nakazono M; Yamamoto H
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):997-1001. PubMed ID: 2214478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance intravesical bacillus calmette-guerin for superficial transitional cell carcinoma of bladder. A retrospective study.
    Schwalb DM; Addonizio JC; Camilleri J; Choudhury MS; Eshghi M
    Urology; 1990 Sep; 36(3):222-5. PubMed ID: 2392811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.